Medical device company DexCom (NASDAQ: DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates.

Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS expectations. Management attributed quarterly growth to increased continuous glucose monitoring (CGM) adoption among people with type 2 diabetes, particularly following expanded insurance coverage and deeper reach into primary care. Interim CEO Jacob Leach emphasized the impact of new product features and improved access, but also acknowledged lingering manufacturing and sensor deployment issues that affected sensor supply and user experience. As Leach stated, "We have addressed deployment challenges and continue to improve sensor quality, but will not be satisfied until every customer expectation is met."

Looking ahead, DexCom has raised its revenue outlook for the full year, underpinned by expectations of continued growth in type 2 diabetes coverage and the planned rollout of the G7 15-day system. Management highlighted the potential for expanded insurance access and the upcoming release of clinical trial data for non-insulin users as critical factors for future growth. However, CFO Jereme Sylvain cautioned that margin improvement may take time, citing ongoing investments in R&D and customer support. Leach noted, "We are preparing for broader coverage and new product launches, while closely monitoring cost dynamics and manufacturing efficiency as we head into next year."

Key Insights from Management’s Remarks

DexCom’s leadership credited the quarter’s growth to expanding access for type 2 diabetes patients, new product features, and international market strength, while acknowledging cost and quality headwinds.

• Type 2 diabetes coverage expansion: Management pointed to growing insurance coverage for type 2 diabetes, now reaching nearly 6 million U.S. non-insulin lives, fueling new customer starts and supporting broader product adoption.
• International market acceleration: Strong performance in France and Canada was attributed to recent coverage wins, with France showing accelerating growth each quarter following expanded reimbursement for basal insulin users.
• Product innovation and launches: The introduction of DexCom Smart Basal, a personalized insulin titration module, and the ongoing limited launch of the G7 15-day sensor were highlighted as key to improving patient outcomes and driving future adoption.
• Customer experience investment: The company has rolled out new digital platforms, including My DexCom Account, to streamline support and ordering, responding to customer feedback and aiming to differentiate on service quality.
• Quality and supply chain challenges: Higher-than-expected manufacturing scrap rates and recent sensor deployment issues were acknowledged, but management noted improvements and expects further stabilization as new quality controls and shipping methods are implemented.

Drivers of Future Performance

DexCom expects its growth trajectory to be shaped by continued expansion into the type 2 diabetes population, new product launches, and operational improvements aimed at restoring margins.

• Broader access and adoption: Management believes that further insurance coverage for type 2 diabetes—particularly among non-insulin users—will be a major growth driver, supported by new clinical outcomes data and ongoing advocacy with payers.
• Product pipeline execution: The upcoming full launch of the G7 15-day sensor and development of the G8 multi-analyte platform are expected to enhance DexCom’s competitive position and improve both revenue and potential gross margin as manufacturing transitions stabilize.
• Margin recovery focus: Leadership is prioritizing manufacturing efficiency and cost control, with expectations that scrap rates and freight costs will decline as supply chain adjustments take hold, gradually lifting margins through 2026.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace and breadth of expanded type 2 diabetes coverage and evidence readouts from clinical trials, (2) the full commercial launch and adoption rate of the G7 15-day sensor in the U.S. and key international markets, and (3) progress on manufacturing efficiency and cost controls to restore margins. We will also track how new digital tools improve customer satisfaction and retention.

DexCom currently trades at $58.80, down from $68.21 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.